Jose M Trigo1, Alexandra Soliman, Gregory Staios, Lena Quilty, Benedikt Fischer, Tony P George, Jürgen Rehm, Peter Selby, Allan J Barnes, Marilyn A Huestis, Bernard Le Foll. 1. Translational Addiction Research Laboratory, Campbell Family Mental Health, Research Institute (JMT, AS, GS, BLF); Clinical Research (LQ); Social and Epidemiological Research Department (BF, JR); Schizophrenia Division and Complex Mental Illness Program, Centre for Addiction and Mental Health (CAMH), Toronto, Canada (TPG); Addiction Policy, Dalla Lana School of Public Health (JR); Institute of Medical Science, University of Toronto, Faculty of Medicine (BF, JR); Department of Psychiatry, University of Toronto, Toronto, Canada (BF, TPG, JR, PS); Institute of Clinical Psychology and Psychotherapy & Center of Clinical Epidemiology and Longitudinal Studies (CELOS), Technische Universität Dresden, Dresden, Germany (JR); Addictions Division, CAMH (PS, BLF); Department of Family and Community Medicine, University of Toronto, Toronto (PS); Centre for Applied Research in Mental Health & Addiction, Faculty of Health Sciences, Simon Fraser University, Vancouver, Canada (BF); and Chemistry and Drug Metabolism, National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), Baltimore, MD (AJB, MAH).
Abstract
OBJECTIVES: Cannabis is the most commonly used illicit drug; a substantial minority of users develop dependence. The current lack of pharmacological treatments for cannabis dependence warrants the use of novel approaches and further investigation of promising pharmacotherapy. In this case series, we assessed the use of self-titrated dosages of Sativex (1:1, Δ-tetrahydrocannabinol [THC]/cannabidiol [CBD] combination) and motivational enhancement therapy and cognitive behavioral therapy (MET/CBT) for the treatment of cannabis dependence among 5 treatment-seeking community-recruited cannabis-dependent subjects. METHODS: Participants underwent a 3-month open-label self-titration phase with Sativex (up to 113.4 of THC/105 mg of CBD) and weekly MET/CBT, with a 3-month follow-up. RESULTS: Sativex was well-tolerated by all participants (average dosage 77.5 THC/71.7 mg CBD). The combination of Sativex and MET/CBT reduced the amount of cannabis use and progressively reduced craving and withdrawal scores. THC/CBD metabolite concentration indicated reduced cannabis use and compliance with medication. CONCLUSIONS: In summary, this pilot study found that with Sativex in combination with MET/CBT reduced cannabis use while preventing increases in craving and withdrawal in the 4 participants completing the study. Further systematic exploration of Sativex as a pharmacological treatment option for cannabis dependence should be performed.
OBJECTIVES:Cannabis is the most commonly used illicit drug; a substantial minority of users develop dependence. The current lack of pharmacological treatments for cannabis dependence warrants the use of novel approaches and further investigation of promising pharmacotherapy. In this case series, we assessed the use of self-titrated dosages of Sativex (1:1, Δ-tetrahydrocannabinol [THC]/cannabidiol [CBD] combination) and motivational enhancement therapy and cognitive behavioral therapy (MET/CBT) for the treatment of cannabis dependence among 5 treatment-seeking community-recruited cannabis-dependent subjects. METHODS:Participants underwent a 3-month open-label self-titration phase with Sativex (up to 113.4 of THC/105 mg of CBD) and weekly MET/CBT, with a 3-month follow-up. RESULTS:Sativex was well-tolerated by all participants (average dosage 77.5 THC/71.7 mg CBD). The combination of Sativex and MET/CBT reduced the amount of cannabis use and progressively reduced craving and withdrawal scores. THC/CBD metabolite concentration indicated reduced cannabis use and compliance with medication. CONCLUSIONS: In summary, this pilot study found that with Sativex in combination with MET/CBT reduced cannabis use while preventing increases in craving and withdrawal in the 4 participants completing the study. Further systematic exploration of Sativex as a pharmacological treatment option for cannabis dependence should be performed.
Authors: E L Karschner; W D Darwin; R P McMahon; F Liu; S Wright; R S Goodwin; M A Huestis Journal: Clin Pharmacol Ther Date: 2011-02-02 Impact factor: 6.875
Authors: Jose M Trigo; Dina Lagzdins; Jürgen Rehm; Peter Selby; Islam Gamaleddin; Benedikt Fischer; Allan J Barnes; Marilyn A Huestis; Bernard Le Foll Journal: Drug Alcohol Depend Date: 2016-02-23 Impact factor: 4.492
Authors: Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Ahmed Elkashef; Frank Vocci; Marilyn Huestis; Margaret Haney; Alan Budney; Amanda Gruber; Nady el-Guebaly Journal: Subst Abus Date: 2008 Impact factor: 3.716
Authors: Anna E Kirkland; Matthew C Fadus; Staci A Gruber; Kevin M Gray; Timothy E Wilens; Lindsay M Squeglia Journal: Psychiatry Res Date: 2021-12-20 Impact factor: 3.222
Authors: Francisco Navarrete; María Salud García-Gutiérrez; Ani Gasparyan; Amaya Austrich-Olivares; Jorge Manzanares Journal: Front Pharmacol Date: 2021-05-20 Impact factor: 5.810
Authors: Jose M Trigo; Alexandra Soliman; Lena C Quilty; Benedikt Fischer; Jürgen Rehm; Peter Selby; Allan J Barnes; Marilyn A Huestis; Tony P George; David L Streiner; Gregory Staios; Bernard Le Foll Journal: PLoS One Date: 2018-01-31 Impact factor: 3.240
Authors: Anjali K Bhardwaj; David J Allsop; Jan Copeland; Iain S McGregor; Adrian Dunlop; Marian Shanahan; Raimondo Bruno; Nghi Phung; Mark Montebello; Craig Sadler; Jessica Gugusheff; Melissa Jackson; Jennifer Luksza; Nicholas Lintzeris Journal: BMC Psychiatry Date: 2018-05-18 Impact factor: 3.630